National Harbor, Md.—Data from a multicenter trial of a novel targeted immunotherapy for the treatment of persistent/recurrent or metastatic cervical cancer (PRmCC) have yielded historic results: a 12-month overall survival (OS) of 38%, exceeding OS rates of more than 20 other clinical trials conducted in this area over nearly two decades.
“Axalimogene filolisbac is one of the very few active agents identified by rigorous evaluation via clinical trials in patients with PRmCC,”